Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma | 2 Minute Medicine
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Relapsed: D + VD Treatment | DARZALEX® IV (daratumumab)
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
British Journal of Haematology | Wiley Online Library
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
DREAMM Clinical Trial Program
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
British Journal of Haematology | Wiley Online Library
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis - Biology of Blood and Marrow Transplantation
British Journal of Haematology | Wiley Online Library
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
![PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2f0ca3b1a7ecfca0a8a6fce95c955879f5ec3e35/9-Table3-1.png "PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar")
PDF] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. | Semantic Scholar
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Changes in hemoglobin and IgA levels. BDR: bortezomib, dexamethasone,... | Download Scientific Diagram
